What question did this study set out to answer?

To assess the efficacy and safety of GLP-1 receptor agonists in immune-mediated inflammatory disorders.

January 23, 2026

P1064Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review

Key Points

To assess the efficacy and safety of GLP-1 receptor agonists in immune-mediated inflammatory disorders.
Conducted a systematic search in PubMed, Scopus, and Embase for relevant studies.
Included 33 studies reporting on GLP-1 receptor agonists and immune-mediated inflammatory diseases.
Summarized data on clinical and metabolic outcomes without performing meta-analysis due to data heterogeneity.
Outcomes in inflammatory bowel disease showed a lower incidence of new onset in GLP-1 receptor agonist users.
GLP-1 receptor agonists correlated with better disease activity and metabolic outcomes in patients with IMIDs.
Gastrointestinal adverse events were more frequent but mostly non-severe in the GLP-1 receptor agonist cohort.

Abstract

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP1RA) are believed to have anti-inflammatory properties apart from antidiabetic and anti-obesity effects. We performed a systematic review to evaluate the efficacy and safety of GLP1RA in immune-mediated inflammatory disorders (IMIDs). Methods A systematic search was done on 3rd April 2025 in PubMed, Scopus, and Embase for studies reporting the use of GLP1RA among patients with IMIDs. Because of significant heterogeneity and overlapping data originating from the same insurance databases, we decided against performing a data synthesis and meta-analysis. We summarized the data regarding clinical and metabolic outcomes in patients with IMIDs with/without the use of GLP1RA. Results Thirty-three studies (20 full text, 13 conference abstracts) were included, of which 20 studies focused on inflammatory bowel disease (IBD) and 13 on other IMIDs. Of the three studies reporting on new onset IBD/IMID in GLP1RA users, 2 showed a lower incidence. IBD therapy utilization was reported in 13 studies; steroid use was lower in 5 studies, but the data on the use of biologics were inconclusive. Other outcomes, like hospitalisation, IBD complications, surgery, and mortality, seemed to be better in GLP1RA cohorts in a few of the studies. Similarly, psoriasis disease activity-related outcomes were better in the GLP1RA cohort, but the effect on other IMIDs was limited by sparse literature. A total of 12 studies reported metabolic outcomes, including weight loss, glycaemic control, waist circumference, and lipid parameters, all of which showed beneficial effects of GLP1Ras, and these results were comparable to non-IBD/IMID controls. Adverse events (AEs) were reported by 13 studies; gastrointestinal (GI) AEs were higher in the GLP1RA cohort (but the majority were non-severe). Conclusion GLP1RA use is associated with better disease activity and metabolic outcomes in patients with IMIDs and concomitant metabolic disorders. References: 1. Yarur AJ, Bruss A, Moosreiner A, et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology. 2023;165(4):963-975.e5. 2. Desai A, Petrov J, Hashash JG, et al. Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60(5):620-632. 3. Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022;33(3):1428-1434. Conflict of interest: Dr. Birda, Chhagan Lal: No conflict of interest Ibrahim, Fadwa: No conflict of interest Chatterjee, Abhirup: No conflict of interest Jena, Anuraag: No conflict of interest Sharma, Vishal: No conflict of interest Sebastian, Shaji: No conflict of interest

Mark Helpful

Bookmark

Relay